Biomarin Pharmaceutical Inc at Morgan Stanley Healthcare Conference Transcript
We're ready to get started with the next session. I'm Matt Harrison, one of the biotech analysts here. Quickly, before we get started, I just need to read a disclosure statement. Please note that all-important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.
So pleased to have with me Hank Fuchs, who runs R&D; and Dan Spiegelman, who is the CFO of BioMarin. And I think, Dan, you want to make some opening comments, and then we can jump into it.
Yes, sure. Just to start by saying that things are going great right now. The core business of BioMarin is on track to generate about $1.7 billion in revenues this year. We're going to have non-GAAP income growth to put us in the $130 million to $170 million this year. A number of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
